DEPDC1

Official Full Name

DEP domain containing 1

Organism

Homo sapiens

GeneID

55635

Background

Predicted to enable GTPase activator activity. Involved in negative regulation of DNA-templated transcription. Located in nucleus. Part of transcription repressor complex. [provided by Alliance of Genome Resources, Feb 2025]

Synonyms

DEP.8; SDP35; DEPDC1A; DEPDC1-V2;

Cat.No.	Product Name	Price

Cat.No.	Product Name	Price

Cat.No.	Product Name	Price

Cat.No.	Product Name	Price

Detailed Information

The DEP structural domain is a globular domain consisting of approximately 90 amino acids that was first identified in three proteins: D. melanogaster Dishevelled, C. elegans EGL-10, and mammalian Pleckstrin, which are involved in Wnt signaling, G protein-coupled receptor signaling, and platelet and neutrophil signaling, respectively. These proteins are involved in Wnt signaling, G protein-coupled receptor signaling and platelet and neutrophil signaling, respectively.

Role of DEPDC1 in Tumor Development and Progression

DEPDC1 (DEP domain containing 1), Several studies have shown that DEPDC1 is aberrantly overexpressed in a wide range of human cancers and acts as an oncogene during tumorigenesis and progression. In a former study, the essential requirement of DEPDC1 to accelerate cell cycle progression and movement through the NF-κB signaling pathway in nasopharyngeal carcinoma has been reported. In other study, researchers found that DEPDC1 plays an oncogenic role in prostate cancer through activation of E2F signaling, which has a broad impact on the progression of HCC.

DEP domain containing 1 (DEPDC1) is a highly conserved protein that has been reported to act as a transcriptional repressor in bladder cancer cells. It represses A20 transcription by forming a complex with ZNF224, which activates the anti-apoptotic pathway through NF-κB via activation of NF-κB. A recent report showed that DEPDC1 promotes JNK-dependent degradation of MCL1 (an anti-apoptotic cell) in HeLa and MCF-7 cells, thereby inhibiting apoptosis. Thus, apoptosis was inhibited. Several reports in bladder, breast and lung cancers suggest that upregulation of DEPDC1 may play an important role in tumor-igenesis.

Molecular Targeted Therapy Strategies against DEPDC1

Given the critical role of DEPDC1 in tumor development and progression, molecular targeted therapy strategies against this gene have gained significant attention. Strategies include gene amplification, gene transfer, and small molecule inhibitors. Preclinical studies have shown that restoring DEPDC1 expression in tumor cells can inhibit tumor growth and metastasis. Moreover, targeting DEPDC1 has the potential to enhance the efficacy of existing cancer therapies and reduce drug resistance.

References:

Wang Q, Li A, Jin J, Huang G. Targeted interfering DEP domain containing 1 protein induces apoptosis in A549 lung adenocarcinoma cells through the NF-κB signaling pathway. Onco Targets Ther. 2017;10:4443-4454. Published 2017 Sep 11. doi:10.2147/OTT.S142244
Shen X, Han J. Overexpression of gene DEP domain containing 1 and its clinical prognostic significance in colorectal cancer. J Clin Lab Anal. 2020;34(12):e23634. doi:10.1002/jcla.23634

Quick Inquiry

Interested in learning more?

Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.

Request a quote today!

Inquiry